Morgan Brown - Lipocine CFO, Executive Vice President
| LPCN Stock | USD 5.27 0.17 3.13% |
President
Mr. Morgan R. Brown CPA, was appointed as Chief Financial Officer, Executive Vice President of Lipocine Inc., with effect from September 16, 2013. Mr. Brown has more than 20 years of financial and accounting experience, including over 13 years in financial management of life science companies. Most recently, Mr. Brown was the CFO at Innovus Pharmaceuticals, Inc. . Previously he was the CFO of World Heart Corporation and Lifetree Clinical Research and the Vice President, Finance and Treasurer of NPS Pharmaceuticals, Inc. . Before NPS Pharmaceuticals Mr. Brown was a Senior Manager at KPMG LLP since 2013.
| Age | 46 |
| Tenure | 11 years |
| Address | 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 |
| Phone | 801 994 7383 |
| Web | https://www.lipocine.com |
Lipocine Management Efficiency
The company has return on total asset (ROA) of (0.3702) % which means that it has lost $0.3702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.584) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of April 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to grow to -0.7. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 20th of April 2024, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Shane Cooke | Alkermes Plc | 54 | |
| Robert Janssen | Dynavax Technologies | 70 | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Rebecca Peterson | Alkermes Plc | 38 | |
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Craig Hopkinson | Alkermes Plc | 49 | |
| Michael Landine | Alkermes Plc | 70 | |
| David Johnson | Dynavax Technologies | 56 | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
| Christopher Wright | Ironwood Pharmaceuticals | N/A | |
| Gordon Pugh | Alkermes Plc | 57 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Mark Stejbach | Alkermes Plc | 55 | |
| David Gaffin | Alkermes Plc | 52 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.37 |
Lipocine Leadership Team
Elected by the shareholders, the Lipocine's board of directors comprises two types of representatives: Lipocine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipocine. The board's role is to monitor Lipocine's management team and ensure that shareholders' interests are well served. Lipocine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipocine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Ono, Director | ||
| Jeffrey Fink, Director | ||
| CPA CPA, Co Sec | ||
| Stephen Hill, Lead Independent Director | ||
| Gregory Bass, Executive Vice President Chief Commercial Officer | ||
| Logan Morse, Marketing Sales | ||
| John Higuchi, Non-Executive Director | ||
| Nachiappan Chidambaram, Senior Development | ||
| M MD, Chief Director | ||
| Mahesh Patel, Co-Founder, Chairman, CEO and Pres | ||
| Krista Fogarty, Principal Controller | ||
| Morgan Brown, CFO, Executive Vice President |
Lipocine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipocine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (12.00) % | ||||
| Current Valuation | 7.31 M | ||||
| Shares Outstanding | 5.32 M | ||||
| Shares Owned By Insiders | 3.03 % | ||||
| Shares Owned By Institutions | 9.16 % | ||||
| Number Of Shares Shorted | 108.89 K | ||||
| Price To Earning | 15.80 X | ||||
| Price To Book | 1.47 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lipocine in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lipocine's short interest history, or implied volatility extrapolated from Lipocine options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Lipocine Stock analysis
When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share (0.54) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.